Concert Genetic Testing: Endocrinology — Monogenic Diabetes (MODY) Panels
Customize your policy alerts
Sign up for all Arizona Complete Health policy alerts
Know when Arizona Complete Health releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity criteria for genetic testing panels used to diagnose monogenic diabetes (including MODY) and related endocrine genetic tests for members of Arizona Complete Health. Applies to providers ordering Concert genetic tests for endocrine indications.
Changed requirement from diabetes diagnosis within first 6 months of life to within the first 12 months of life for neonatal testing.
Changed age cutoff for testing from diagnosis before age 35 years to diagnosis before age 30 years.
Removed requirement for specific gene inclusion in panels and reworded antibody and C-peptide criteria to be less prescriptive.
New policy created to separate endocrine genetic testing from prior metabolic/endocrine/mitochondrial policy.
Coverage Criteria — Monogenic Diabetes and Related Panels
Monogenic Diabetes (Including MODY) Panels
Multigene panel analysis to establish or confirm a diagnosis of monogenic diabetes (including MODY) is considered medically necessary when:
neonatal diabetes indication
Younger-onset pathway
- At least one of: a) Autoantibody negative
- At least one of: b) Retained C-peptide levels
MODY suspicion with autosomal dominant pattern
Unsupported / investigational uses
Not supported indications
investigational/unproven for unspecified indications
This policy addresses the scope and limits for use of multigene panel analysis to diagnose monogenic forms of diabetes (including MODY). Multigene panels are considered medically necessary only when they are used to establish or confirm a diagnosis in patients who meet the specific criteria listed in the policy — for example, a diabetes diagnosis within the first 12 months of life; a diagnosis before 30 years of age combined with supportive features such as autoantibody negativity or retained C‑peptide; or a diabetes phenotype not characteristic of type 1 or type 2 diabetes with an autosomal dominant family history. The policy does not require panels to include predefined gene lists and intentionally removes prescriptive numeric laboratory cutoffs to align with current evidence and guideline updates.
Routine or reflex use of multigene panels for monogenic diabetes outside the defined criteria is not supported by current evidence. The policy explicitly states that multigene panel analysis is not supported for all other indications beyond the specific criteria described, and such testing should not be performed routinely when the listed clinical thresholds and indications are not met.
Coding and Key Clinical Thresholds
| 81403 | tiered molecular multigene panel (as referenced in policy) |
| 81405 | tiered molecular multigene panel (as referenced in policy) |
| 81406 | tiered molecular multigene panel (as referenced in policy) |
| 81407 | tiered molecular multigene panel (as referenced in policy) |
| 81479 | unlisted molecular pathology procedure (as referenced in policy) |
| E10 | Type 1 diabetes mellitus (ICD-10 listed in table) |
| E11 | Type 2 diabetes mellitus (ICD-10 listed in table) |
| E16.1 | Other hypoglycemia (ICD-10 listed in table) |
| E16.2 | Hypoglycemia, unspecified (ICD-10 listed in table) |
Provider Actions, Authorization & Documentation
Prior Authorization Required
Prior authorization is required for the listed CPT multigene panel codes when medical necessity criteria are met. Submit prior authorization requests with relevant clinical information that demonstrates how the member meets the policy criteria (for example: age at diagnosis, antibody status, C‑peptide results, family history, and indication). Authorization is actionable only when the submitted documentation supports the policy's medical necessity requirements.
- Affected tests: multigene panel CPT codes referenced in this policy (see code table or Concert Platform).
- Authorization must be obtained prior to claim submission for services requiring PA.
Coding and Coverage Caveat
Providers must ensure appropriate coding and understand that listing a CPT code in this policy does not guarantee coverage. Verify coding and coverage with the most current professional coding resources and the payer prior to claim submission. Use the Concert Platform or payer-specific guidance for up-to-date test registries and coverage status.
- Inclusion of a CPT code in this policy is for informational purposes only.
- Confirm coverage and billing expectations (e.g., specimen requirements, billing modifiers) with Arizona Complete Health before submitting claims.
Counseling and Clinical Documentation
Pre-test and post-test genetic counseling is strongly advised to facilitate informed decision-making, address the possibility of secondary or incidental findings, and establish a plan for returning results. Document counseling in the medical record, including the informed consent discussion, risks/limitations, potential implications for family members, and the plan for result disclosure.
- Documented elements: indication for testing, informed consent for genetic testing, discussion of possible secondary/incidental findings, and plan for result communication to patient and family.
- If applicable, include laboratory requisition, relevant prior testing (autoantibodies, C‑peptide), and family history pedigree or summary.
Provider Documentation & Denial Risk
Provider action: include necessary documentation to support medical necessity and prior authorization decisions. Failure to provide requested documentation may result in denial of the authorization or claim. Check payer-specific submission requirements for required forms or portals.
- Ensure medical records contain the clinical data referenced in the policy (age at diagnosis, antibody results, C‑peptide, family history).
- Respond to requests for records or additional information from the payer in a timely manner to avoid delays or denials.
Background and Scope
This policy covers genetic testing to evaluate monogenic causes of diabetes, including neonatal diabetes and maturity‑onset diabetes of the young (MODY). The rationale reflects recent updates to align with guideline and evidence reviews: age thresholds were revised to require diagnosis within the first 12 months for neonatal testing and diagnosis before 30 years for one younger‑onset pathway; antibody and C‑peptide language was clarified rather than using strict numeric cutoffs; and panel composition is no longer prescriptive. Pre‑test and post‑test genetic counseling and clinical documentation of age at diagnosis, antibody status, C‑peptide, family history, and atypical phenotype are strongly advised.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.